News

AMSBIO announces XerumFree™ - a new concept in cell culture that allows you to culture cells without the use of serum.

XerumFree™ has been developed taking into account what is missing in traditional basal cell culture media to sustain growth of all cell types, which is a nutritional approach at the cellular level. 

Detachin™ Cell Detachment Solution from AMSBIO is a high-performance alternative to Trypsin/EDTA for detaching adherent cells from in vitro growth vessels. Detachin™ provides rapid, gentle, and effective detachment of a wide variety of adherent cells, including primary cells, from all commercially available tissue culture plasticware.

AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology.



Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.

AMSBIO is a leading supplier of gold, silver and platinum coated substrates for nanotechnology researchers looking to use these surfaces to characterize self-assembled monolayers using atomic force microscopy (AFM), or scanning tunneling microscopy (STM).



Gold, silver and platinum surfaces offer a clean, near atomically-flat surface that is ideal for applications in nanotechnology, such as studies on self-assembly, single-molecule imaging, nano- or micro-contact printing, DNA origami, or nanophotonics.

AMSBIO offers an unmatched portfolio of over 2000 tissue microarrays (TMAs), one of the best sample formats for rapid detection of cellular localization of RNA and protein expression.

AMSBIO has added a new range of GCaMP calcium indicators (jGCaMP7b, jGCaMP7c, jGCaMP7f, jGCaMP7s) to their portfolio of ready-to-use adeno-associated virus (AAV) biosensor products. These viruses encoded biosensors are supplied ready for use for neural activity studies in vivo.

While One Nucleus CEO Tony Jones attended the Future of Swedish & Danish Life Science 2019 at Medicon Village last week, Marks & Clerk had Norway covered by co-hosting and co-sponsoring the UT Conference in London. Simon Portman of Marks & Clerk Law gave a contracts training seminar for Norwegian tech companies and Matt Pinney of Marks & Clerk brought them up to speed on the patentability of AI.


Medicines Discovery Catapult integrates Alderley Park’s imaging services and expertise, further enhancing preclinical imaging capabilities


Today [9 April 2019], Medicines Discovery Catapult has agreed with Alderley Park Ltd to integrate Alderley Park’s imaging services and expertise into their pre-clinical imaging capability, further enhancing their offering to UK SMEs.

LabKey, a US-based custom informatics solution provider, offering a freely-accessible, enterprise-quality, open source software platform to help research organisations solve their research data challenges.


In February 2016, LabKey opened its UK office, appointing Dr Jason Leadley, as its Director of European Operations. Relying heavily on engagements driven by the download and use of its open source, Community Edition of its core software platform, LabKey Server.

Kadans enters the UK life science market by acquiring from Imperial College ThinkSpace the B900 building located on the Babraham Research Campus (“BRC”) in Cambridge, adding to its Pan-European science park portfolio. The fully let property accommodates two companies (Abzena and Bicycle Therapeutics) active in the field of cancer and immunology therapeutics, forming a welcome addition to Kadans existing science partner network including tenants such as Genmab, Merus and MDxHealth.

Pages